Seasonal influenza virus vaccine intranasal - BioDiem

Drug Profile

Seasonal influenza virus vaccine intranasal - BioDiem

Alternative Names: LAIV; LAIV Seasonal intranasal; Live attenuated influenza vaccine - BioDiem; Nasovac-S; SCH-900795; Seasonal influenza virus vaccine (intranasal) - BioDiem; Trivalent seasonal influenza virus vaccine - Serum Institute of India/Biodiem

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Developer BioDiem; Changchun BCHT Biotechnology; Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Class Attenuated vaccines; Influenza virus vaccines-live; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 14 Sep 2017 Changchun BCHT Biotechnology completes a phase III trial in Influenza virus infections (In adolescents, In children, Prevention) in China (Intranasal) (NCT02964065)
  • 01 Nov 2016 Phase-III clinical trials in Influenza virus infections (In adolescents, In children, Prevention) in China (Intranasal) (NCT02964065)
  • 22 Jun 2015 No recent reports on development identified - Phase-II for Influenza virus infections (Prevention) in European Union (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top